NIH Grant Success Rates Under 20%: How to Write a Proposal That Wins in 2026

Last verified: April 18, 2026.

The short version. NIH R01 success rates for early-stage investigators have dropped from 29.8% to 18.5% in two years, and the multiyear forward-funding policy will eliminate an estimated 970 more competing grants in FY2026. The long version of this post explains exactly why that happened. The more useful version — and the one most researchers need right now — is the 5-step playbook at the bottom on how to write an NIH proposal that still wins when the payline has fallen: target institutes strategically, resubmit the one closest to the line, use ESI-friendly mechanisms, diversify beyond NIH, and build multi-PI collaborations that draw from different budget pools.

One in four early-career scientists who applied for a major NIH grant won one two years ago. Now it's fewer than one in five — and the math is about to get worse.

New data from NIH's Research Portfolio Online Reporting Tools show that success rates for early-stage investigators seeking R01-equivalent grants fell from 29.8% in fiscal year 2023 to 18.5% in 2025. That's an 11-percentage-point collapse in two years. The number of early-stage investigators actually receiving awards dropped from over 1,400 in 2024 to 1,144 in 2025. At the National Cancer Institute, the odds went from roughly one in 10 to one in 25.

Established investigators weren't spared. Their success rates dropped from approximately 27% to 20% over the same period. Across all categories, the total number of investigators winning R01-equivalent grants fell from 7,720 in 2024 to 5,885 in 2025.

These numbers predate the next hit: NIH's multiyear forward-funding policy, which will eliminate an estimated 970 additional competing grants in fiscal year 2026.

How Multiyear Funding Shrinks the Pool

Traditionally, NIH funds grants incrementally — each year's appropriation covers that year's costs for continuing grants, freeing the rest for new awards. Under the multiyear funding policy, introduced in FY2025 and continued in FY2026, NIH reserves a portion of its budget to fund grants across their entire duration upfront. A three-year R01 might be fully funded from a single year's appropriation rather than drawing from three separate years.

The appeal for NIH is budget flexibility. By front-loading commitments, the agency avoids being locked into future-year obligations that constrain spending decisions. The cost is immediate: upfront funding for multiyear grants consumes dollars that would otherwise support new awards.

The scale of the shift is striking. In FY2024, NIH committed $1.4 billion to multiyear-funded grants, representing 16.2% of new and competing grant funding. In FY2025, that jumped to $3.61 billion — 30.1% of competing grants. The number of R01 grants receiving multiyear funding exploded from 21 in FY2024 to 743 in FY2025.

Congress noticed. The Senate Appropriations Committee expressed concern that the policy "would significantly reduce the number of grants NIH is able to fund" and included language in the final FY2026 bill capping multiyear funding at FY2025 levels. But FY2025 levels are already elevated, and the modeling suggests the cap still translates to roughly 970 fewer competing awards than historical norms would produce.

Who Gets Squeezed

The decline is hitting early-career scientists hardest, which is precisely the population NIH has historically tried to protect. NIH's early-stage investigator (ESI) policy was designed to give new researchers a leg up — ESI applications receive special consideration during peer review, and institutes track ESI funding rates separately.

That safety net is fraying. The National Heart, Lung, and Blood Institute reported its ESI success rate dropped from 31% to 21%. When early-career success rates converge with established-investigator rates, the pipeline signal is clear: becoming an independent NIH-funded researcher is getting dramatically harder.

The downstream effects compound. Fewer funded investigators means fewer labs hiring postdocs. Fewer active R01s means fewer preliminary data sets for the next generation of proposals. Universities that calibrate faculty hiring to NIH funding levels will pull back. The contraction feeds itself.

How to Win an NIH R01 in 2026: The 5-Step Playbook

The funding landscape is tighter, but it isn't closed. The researchers who keep their labs funded through a contraction don't just write harder — they pick targets differently, sequence submissions differently, and hold a broader funding portfolio than they did three years ago. Here's the five-step playbook that separates the investigators who adapt from the investigators who wait for appropriations to bounce back.

1. Target institutes strategically — each of the 27 sets its own payline. NIH institutes are not one funding pool with a uniform success rate; they are 27 separate funding pools with 27 separate strategies for absorbing the multiyear-funding squeeze. NICHD published detailed FY2026 guidance explaining exactly how it will prioritize competing awards. NCI's public dashboard shows which divisions are still above payline and which are well below. NIDA and NIMH publish their R01 success rates by mechanism every quarter. Before you choose which institute to submit to, read the target institute's funding strategy page, its most recent Council meeting notes, and any published payline. Pick the institute whose strategic priorities most obviously align with your aims, not the one whose name sounds closest to your disease area.

2. Resubmit the one closest to the line — don't scatter. With fewer awards available per cycle, reviewers can afford to be more selective about what they fund and more decisive about what they send back. If your application scored close to the payline but wasn't funded, a strong A1 resubmission that directly addresses every reviewer critique is your single highest-probability path to funding this year. The temptation is to respond to rejection by submitting three new applications in parallel — don't. Three half-revised proposals will lose to one fully revised proposal in a tight year. Invest the cycle in the one application closest to the line, read the reviewer summary statement line by line, and answer every concern in the introduction to the revised application.

3. Use ESI-friendly mechanisms — R21, R03, and the K-series change the math. The R01 is not the only entry point, and in a compressed funding cycle it may not be the smartest one. The R21 (exploratory/developmental, $275K direct over two years) and R03 (small grant, $100K direct over two years) have different review dynamics than R01s — more tolerance for high-risk work, less demand for extensive preliminary data. The K-series career development awards (K01, K08, K23, K99/R00) remain the single strongest bridge for early-career investigators who need protected research time and preliminary data before competing for an R01. An NHLBI ESI whose odds of a direct R01 are now 21% may have 30%+ odds of a K99/R00 in the same cycle — and the K99/R00 lands them at an independent institution with R01-eligible credentials.

4. Diversify beyond NIH — NSF, DOD, DOE, and foundations fund the same biology. NIH is not the only funder of biomedical research. NSF's Directorate for Biological Sciences funds fundamental biology that overlaps heavily with NIH-funded mechanisms. DOD's CDMRP committed $1.27 billion across FY2026 disease-specific programs — breast cancer, prostate cancer, ALS, Peer Reviewed Medical Research, and more — and the CDMRP review cycle runs on a different calendar than NIH study sections. DOE funds quantitative biology through its Biological and Environmental Research program. And the private foundation landscape is large: the MacArthur Foundation deployed $10 million in AI-for-public-interest grants in 2025; the Humanity AI coalition committed $500 million over five years; the Chan Zuckerberg Initiative runs a continuous Imaging Scientists and Single-Cell Analysis pipeline. If your research intersects with defense health, mental health, AI, climate, or technology policy, there are parallel funding streams that don't depend on NIH's constrained paylines.

5. Build multi-PI collaborations — team mechanisms draw from different budget pools. The P01 program project grant, the U01 cooperative agreement, the P30 center grant, and the multi-PI R01 all draw from different budget lines than the single-investigator R01. These mechanisms face different compression dynamics, and the review criteria weight collaborative breadth heavily. If your science fits a team-based model — multi-site clinical research, cross-disciplinary discovery, shared-resource cores — a well-assembled multi-PI proposal can outperform three competing single-PI R01s from the same group. Start conversations with potential co-investigators 6-12 months before the target deadline, because the proposal-writing phase on team grants is longer than most people plan for.

Where Granted fits

Running steps 1, 4, and 5 by hand is where most labs lose time. Tracking 27 NIH institute paylines, 12 DOD CDMRP disease programs, 4 relevant NSF directorate calls, and the 133,000-foundation private landscape — and actually knowing which are open on any given day — is not realistic as a side task on top of the science. Granted indexes every NIH NOFO, NSF program, DOD CDMRP track, DOE BER solicitation, and private foundation (133,000+ foundations, pulled from IRS 990 filings) with live deadlines, eligibility rules, and historical award sizes. Filter by disease area, mechanism, institute, or institution, and the prospect list for your next submission cycle builds itself in minutes rather than weeks.

The Structural Problem

Congress gave NIH a modest increase in FY2026 — the final bill landed at $47.2 billion, up from $46.8 billion. That's real money, but it's not enough to offset both the multiyear funding drain and biomedical inflation that erodes purchasing power by 3-4% annually. To fully compensate for the multiyear policy's impact and maintain historical grant numbers, appropriations would need to increase by 4-6.7%, according to modeling by research policy analysts.

The political appetite for that kind of increase doesn't exist right now. Which means the squeeze on success rates isn't a one-year anomaly — it's the new baseline.

For researchers navigating this environment, the imperative is clear: write sharper proposals, target strategically, and don't put all your funding eggs in one basket. Granted can help surface the right opportunities and move from prospect list to polished submission before the deadline closes.